Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Open-Label Tolvaptan Study in Subjects With ADPKD (TEMPO 4/4)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Otsuka Pharmaceutical Development & Commercialization, Inc.
ClinicalTrials.gov Identifier:
NCT01214421
First received: September 26, 2010
Last updated: May 4, 2016
Last verified: May 2016